OncoMethylome Raises €3.3M, Bringing IPO Proceeds up to €25.3M

Following its initial public offering and Euronext listing on June 27, OncoMethylome Sciences said last week that it has raised an additional €3.3 million ($4.2 million) through the exercise of over-allotment option by Fortis and ING, the joint lead managers in the offering.

OncoMethylome granted the option on up to 440,000 new shares, at the IPO price of €7.5 ($9.5) per share.

As a result, the company's proceeds from the IPO total €25.3 million ($32.2 million).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.